Annexin A1 Is Associated with Adverse Clinical Outcomes in Patients with COVID-19

Severe coronavirus disease 2019 (COVID-19) is characterized by hyperinflammation, vascular damage, and hypercoagulability. Insufficient responses of Annexin A1 (AnxA1), a pro-resolving inhibitor of neutrophil infiltration and activation, might contribute to a severe course of the disease. We longitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Busch, Matthias H., Timmermans, Sjoerd A. M. E. G., Aendekerk, Joop P., Ysermans, Renée, Amiral, Jean, Damoiseaux, Jan G. M. C., Reutelingsperger, Chris P., van Paassen, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781714/
https://www.ncbi.nlm.nih.gov/pubmed/36556102
http://dx.doi.org/10.3390/jcm11247486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781714/
https://www.ncbi.nlm.nih.gov/pubmed/36556102
http://dx.doi.org/10.3390/jcm11247486

Ejemplares similares